Altria Group, Inc. filings document formal disclosures for a U.S. tobacco and nicotine-products operating company. Form 8-K reports cover quarterly and annual results, consolidated financial statements, internal control reporting, material governance changes and completed debt issuances. The filings identify registered securities including MO common stock and exchange-listed notes, and describe senior unsecured notes and guarantees by Philip Morris USA.
Proxy materials cover annual meeting voting matters, director elections, board practices, executive compensation and pay-versus-performance disclosures. The record also includes capital-structure and financial-reporting disclosures tied to Altria's operating subsidiaries, shareholder returns, tobacco and health litigation items, FDA-regulated smoke-free products and other matters affecting its regulated consumer-products business.
Salvatore Mancuso, EVP & CFO of Altria Group, Inc. (MO), reported a transaction dated 08/21/2025 in which 15,496 shares of common stock were disposed of at a price of $67.58 per share. The filing states these shares were withheld to satisfy taxes on the vesting of restricted stock units. After the transaction, Mancuso beneficially owned 255,118 shares in total, which includes 83,537 restricted stock units. The filing also reports 5,559 shares held indirectly in the Altria Deferred Profit-Sharing Plan. The form is signed and dated 08/25/2025.
Altria Group (MO) Q2-25 10-Q highlights
For the six months ended 6/30/25, net revenues fell 3.6% YoY to $11.36 bn while net earnings declined 41.8% to $3.46 bn (EPS $2.04 vs $3.41). The prior-year period included a $2.7 bn gain from the sale of IQOS U.S. rights. Ex-gain, operating trends were steadier: gross profit up 2.1% to $7.10 bn; operating income down 3.6% to $5.02 bn after a $873 m non-cash goodwill impairment tied to the e-vapor unit.
Segment OCI: Smokeable products rose 2.9% to $5.40 bn; oral tobacco surged 75% to $0.93 bn, offset by a $1.12 bn loss in “All Other” (e-vapor, Horizon, etc.).
Cash & leverage: Operating cash flow increased to $2.93 bn (vs $2.80 bn), but cash & equivalents dropped to $1.29 bn from $3.13 bn at 12/31/24 following $600 m of share buybacks and $1.61 bn debt repayment. Long-term debt stands at $23.65 bn; book equity remains negative at $(3.21) bn.
Capital returns: A new $1 bn repurchase program was authorized in Jan-25; $0.6 bn completed, $0.4 bn remains. Dividends declared YTD totaled $3.45 bn ($2.04 / share).
Key events: • ITC exclusion order removed NJOY ACE from U.S. market, triggering the goodwill write-down. • No new share restrictions on subsidiaries’ dividend capacity. • Contingent consideration for NJOY flavor PMT approvals increased by $25 m to $45 m.
Liquidity appears sufficient with $2.6 bn unused under an October-2028 revolving credit facility, but ongoing litigation and regulatory actions remain contingencies.